Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × triciribine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hematologic Neoplasms 1 Breast Neoplasms 1

Interventions

Carboplatin 291 Paclitaxel 285 Bevacizumab 153 pembrolizumab 94 liposomal doxorubicin 90 Gemcitabine 87 olaparib 83 Cyclophosphamide 83 Cisplatin 82 Topotecan 78 niraparib 65 Docetaxel 52 Doxorubicin 47 Taxes 41 Drug Therapy 39 fludarabine 36 Nivolumab 34 Filgrastim 32 Specimen Handling 30 Magnetic Resonance Spectroscopy 30 Surveys and Questionnaires 29 Hyperthermic Intraperitoneal Chemotherapy 29 Etoposide 28 Blood Specimen Collection 25 durvalumab 23 Peripheral Blood Stem Cell Transplantation 23 Immunoglobulin G 23 Disulfides 23 Biopsy 23 Cytoreduction Surgical Procedures 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01690468 2020-09-24

PTX-200 and Carboplatin in Ovarian Cancer

Prescient Therapeutics, Ltd.

Phase 1/2 Terminated

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡